Mouse glutamate carboxypeptidase II (GCPII) has a similar enzyme activity and inhibition profile but a different tissue distribution to human GCPII

Tomáš Knedlík1,2, Barbora Vorlová1,3, Václav Navrátil1,2, Jan Tykovart1,2,†, František Sedláčk1,3,4, Simon Vaculín5, Miloslav Franěk5, Pavel Sácha1 and Jan Konvalinkal1,2

1 Institute of Organic Chemistry and Biochemistry of the Czech Academy of Sciences, Prague, Czech Republic
2 Department of Biochemistry, Faculty of Science, Charles University, Prague, Czech Republic
3 First Faculty of Medicine, Charles University, Prague, Czech Republic
4 Department of Genetics and Microbiology, Faculty of Science, Charles University, Prague, Czech Republic
5 Department of Normal, Pathological and Clinical Physiology, Third Faculty of Medicine, Charles University, Prague, Czech Republic

Glutamate carboxypeptidase II (GCPII), also known as prostate-specific membrane antigen (PSMA) or folate hydrolase, is a metallopeptidase expressed predominantly in the human brain and prostate. GCPII expression is considerably increased in prostate carcinoma, and the enzyme also participates in glutamate excitotoxicity in the brain. Therefore, GCPII represents an important diagnostic marker of prostate cancer progression and a putative target for the treatment of both prostate cancer and neuronal disorders associated with glutamate excitotoxicity. For the development of novel therapeutics, mouse models are widely used. However, although mouse GCPII activity has been characterized, a detailed comparison of the enzymatic activity and tissue distribution of the mouse and human GCPII orthologs remains lacking. In this study, we prepared extracellular mouse GCPII and compared it with human GCPII. We found that mouse GCPII possesses lower catalytic efficiency but similar substrate specificity compared with the human protein. Using a panel of GCPII inhibitors, we discovered that inhibition constants are generally similar for mouse and human GCPII. Furthermore, we observed highest expression of GCPII protein in the mouse kidney, brain, and salivary glands. Importantly, we did not detect GCPII in the mouse prostate. Our data suggest that the differences in enzymatic activity and inhibition profile are rather small; therefore, mouse GCPII can approximate human GCPII in drug development and testing. On the other hand, significant differences in GCPII tissue expression must be taken into account when developing novel GCPII-based anticancer and therapeutic methods, including targeted anticancer drug delivery systems, and when using mice as a model organism.

Glutamate carboxypeptidase II (GCPII; EC 3.4.17.21) is a membrane metalloprotease that has been studied intensively over the past 20 years in three different scientific fields: neuroscience, prostate oncology, and dietology. In humans, GCPII is expressed predominantly in the brain [1,2], prostate [3,4], small intestine

Abbreviations
Avi-hGCPII, recombinant extracellular human GCPII; Avi-mGCPII, recombinant extracellular mouse GCPII; GCPII, glutamate carboxypeptidase II; GCPIII, glutamate carboxypeptidase III; NAAG, N-acetyl-l-aspartyl-l-glutamate; PSMA, prostate-specific membrane antigen.
[5], and kidney [4,6]. Because GCPII plays different physiological roles in these tissues, three alternative names for the enzyme have historically been used: N-acetylated alpha-linked acidic dipeptidase (NAALADase) [7], prostate-specific membrane antigen (PSMA) [8], and folate hydrolase [5].

In contrast to the expression pattern of human NAAG-hydrolyzing and folate hydrolase activities [29], mouse GCPII is expressed in largest amounts [29]. In the current study, we prepared and characterized recombinant mouse GCPII and compared it with its human counterpart. We put a strong focus on distribution of GCPII in mouse tissues, as this information is highly relevant for the development of novel GCPII-based anticancer and neuroprotective therapies using mouse models.

In the current study, we prepared and characterized recombinant mouse GCPII and compared it with its human counterpart. We put a strong focus on distribution of GCPII in mouse tissues, as this information is highly relevant for the development of novel GCPII-based anticancer and neuroprotective therapies using mouse models.

Results

Efficient one-step purification method yields purified recombinant mouse GCPII (Avi-mGCPII)

As recombinant extracellular human GCPII was shown to correctly represent the endogenous full-length GCPII [33,34], we prepared the recombinant extracellular part of mouse GCPII (Avi-mGCPII) using a Drosophila S2 expression system, according to the protocol previously established in our laboratory [34]. Avi-mGCPII has a TEV cleavable Avi-tag sequence attached to the N terminus of the mouse GCPII extracellular domain (amino acids 45–752), enabling fast one-step purification (Fig. 1A). Avi-mGCPII was purified from the conditioned medium of cells stably transfected with Avi-mGCPII by affinity chromatography based on the biotin–strep-tavidin interaction [34], yielding 3 mg of pure protein from 1 L conditioned medium (Fig. 1B).

Mouse GCPII has lower catalytic efficiency than human GCPII

To characterize the enzyme activity of Avi-mGCPII, we determined kinetic parameters ($K_M$ and $k_{cat}$) for cleavage of both substrates: N-acetyl-L-aspartyl-L-glutamate (NAAG) and pteroyl-di-L-glutamate (Table 1). The enzymes had similar turnover numbers but differed in their $K_M$ values. The differences were more pronounced for pteroyl-di-L-glutamate than for NAAG. Surprisingly, both enzymes had higher catalytic efficiencies for cleavage of pteroyl-di-L-glutamate than for NAAG (Table 1).

Furthermore, to analyze the inhibition profile of Avi-mGCPII, we determined $K_i$ values for several commonly used GCPII inhibitors (using pteroyl-di-L-glutamate as a substrate). The set of GCPII inhibitors included 2-(phosphonomethyl)pentanedioic acid...
(2-PMPA) [35], (S)-2-((S)-1-carboxy-3-methylbutyl)ureido)pentanedioic acid (ZJ-43) [36], (S)-2-((S)-1-carboxy-(4-iodobenzamido)pentyl)ureido)pentanedioic acid (DCIBzL) [37], quisqualate, DKFZ-PSMA-11 [38], and beta-citryl-L-glutamate (Table 2). We also tested three compounds recently prepared in our laboratory: JB-352 and JB-277 (originally reported as compounds 3 and 22a [39]) and JS-686 (originally compound 7 [40]).

**Mouse and human GCPII exhibit similar substrate specificities**

To obtain information about the substrate specificity of Avi-mGCPII, we screened 19 different dipeptide libraries of the general formula N-Ac-A-X [where A represents a given single N-terminal amino acid and X represents a mixture of 19 proteinogenic amino acids (all except for cysteine)]. The N-acetylated dipeptide libraries were incubated with the enzymes, and the cleaved amino acids were analyzed by HPLC [41]. As a negative control, the potent and selective GCPII inhibitor 2-PMPA was used to block the specific enzyme activity.

Overall, we found no significant differences in hydrolysis of dipeptide substrates between mouse and human GCPII, as illustrated by heat maps showing mouse and human GCPII processing of individual N-acetylated dipeptides (Fig. 2). The enzymes exhibited a clear preference for glutamate in the C-terminal position (i.e., glutamate carboxypeptidase activity); mouse GCPII possesses higher selectivity toward the C-terminal glutamate.

**GCPII is highly expressed in mouse kidney, brain, and major salivary glands**

To analyze GCPII distribution in mouse tissues, we collected tissue samples from six mice (three females and three males) and analyzed them by western blot using the anti-GCPII antibody GCP-04 [2,42]. Mouse GCPII was expressed predominantly in the mouse kidney and brain (Fig. 3), which is in agreement with previous data [9]. Interestingly, we observed high and variable expression in the mouse major salivary glands. The different apparent molecular weights are likely caused by different glycosylation of GCPII in the tissues.

We also determined the NAAG-hydrolyzing activity in the tissue lysate samples using tritium-labeled NAAG as a substrate and compared these results with Table 1.

**Table 1.** Kinetic parameters of recombinant mouse and human GCPII (Avi-mGCPII and Avi-hGCPII, respectively) for their substrates. Kinetic parameters (K_M and k_cat) of N-acety-L-aspartyl-L-glutamate (NAAG) and pteroyl-di-L-glutamate cleavage were determined using radioenzymatic [34] and HPLC assays [39], respectively. The values shown are mean ± standard deviation of duplicate measurements.

| Enzymes     | K_M [nM]   | k_cat [s^{-1}] | k_cat/K_M [× 10^7 s^{-1} M] |
|-------------|------------|----------------|------------------------------|
| Avi-mGCPII  | 1900 ± 100 | 1.44 ± 0.02    | 0.077 ± 0.001                |
| Avi-hGCPII  | 550 ± 60   | 1.45 ± 0.04    | 0.265 ± 0.007                |

| Substrate       | K_M [nM]   | k_cat [s^{-1}] | k_cat/K_M [× 10^7 s^{-1} M] |
|-----------------|------------|----------------|------------------------------|
| NAAG            | 290 ± 20   | 3.63 ± 0.09    | 1.26 ± 0.08                  |
| Pteroyl-di-L-glutamate | 39 ± 2    | 5.09 ± 0.09    | 13.2 ± 0.8                   |

(2-PMPA) [35], (S)-2-((S)-1-carboxy-3-methylbutyl)ureido)pentanedioic acid (ZJ-43) [36], (S)-2-((S)-1-carboxy-(4-iodobenzamido)pentyl)ureido)pentanedioic acid (DCIBzL) [37], quisqualate, DKFZ-PSMA-11 [38], and beta-citryl-L-glutamate (Table 2). We also tested three compounds recently prepared in our laboratory: JB-352 and JB-277 (originally reported as compounds 3 and 22a [39]) and JS-686 (originally compound 7 [40]).

**Fig. 1.** Schematic structure of Avi-mGCPII and affinity purification. (A) Schematic structure of Avi-mGCPII containing an Avi sequence (the biotinylated lysine residue is enlarged and underlined) and TEV protease cleavage sequence (the cleavage site is marked with an asterisk). (B) Silver-stained SDS/PAGE gel showing affinity purification of Avi-mGCPII expressed in Drosophila S2 cells. MWM, molecular weight marker; load, concentrated S2 cell medium; FT, flow-through; W1–W3, wash fractions; E1–E4, elution fractions. Ten microliter samples was loaded onto the gel, except for the E2 fraction (1 µL was loaded).
the data obtained by western blot analysis. Recombinant mouse GCPII was used as a standard, and the observed levels of NAAG-hydrolyzing activity were converted to amounts of GCPII, which were then normalized to the total protein concentrations in the homogenates (Fig. 4).

Table 2. Inhibition of recombinant mouse and human GCPII (Avi-mGCPII and Avi-hGCPII, respectively) by a panel of GCPII inhibitors. Inhibition constants ($K_i$ values) were determined using an HPLC-based assay using pteroyl-di-L-glutamate as a substrate. The values shown are mean ± standard deviation of duplicate measurements.

| Compound                  | $K_i$ (Avi-mGCPII) (nM) | $K_i$ (Avi-hGCPII) (nM) |
|---------------------------|-------------------------|-------------------------|
| Quisqualate               | 580 ± 60                | 520 ± 80                |
| 2-PMPA                    | 0.56 ± 0.05             | 0.26 ± 0.03             |
| ZJ-43                     | 5.9 ± 0.9               | 0.58 ± 0.07             |
| JB-352                    | 0.66 ± 0.06             | 0.17 ± 0.04             |
| β-citrull-L-glutamate     | 24 000 ± 3000           | 16 000 ± 5000           |
| DCIBzL                    | 0.028 ± 0.003           | 0.017 ± 0.002           |
| JB-277                    | 0.68 ± 0.07             | 0.05 ± 0.02             |
| DKFZ-PSMA-11              | 0.10 ± 0.01             | 0.018 ± 0.002           |
| JS-686                    | 0.049 ± 0.005           | 0.021 ± 0.004           |
The results confirmed high expression of GCPII in the kidney, brain, and major salivary glands. We did not detect GCPII in the mouse prostate (Fig. 4).

To further examine the location of GCPII in the highly expressing tissues, we performed immunohistochemistry using the anti-GCPII antibody GCP-04 [2,42]. We found relatively high expression in the white matter in the brain, on luminal side of proximal tubules in the kidney and in the abluminal cells in the major salivary glands (mainly in the sublingual gland) (Fig. 5).

**mRNA expression profile differentiates GCPII and GCPIII expression levels in mouse tissues**

The GCP-04 antibody cross-reacts with GCPIII, which also cleaves NAAG [11,43]. Therefore, we decided to further analyze the tissue distribution of both homologs by quantitative RNA determination (qPCR). For these analyses, we used either commercially available panels of mouse tissue cDNA libraries (Fig. 6A) or cDNA libraries prepared from mouse tissues (female 1 and male 1; Fig. 6B,C).

The results from commercial cDNA libraries represent the average tissue distribution of both transcripts in the mouse population. Each library was pooled from several hundred mice and normalized by the vendor to several different housekeeping genes (beta-actin, G3PDH, phospholipase A2, and ribosomal protein S29). The highest expression of mouse GCPII mRNA was in the kidney, brain, and testis, while mouse GCPIII mRNA was predominantly expressed in the testis, heart, lung, and skeletal muscle (Fig. 6A).

To gain insight into expression of both transcripts in individual mice, we also quantified mRNA transcripts in cDNA libraries prepared from mouse tissues dissected from one female and one male mouse. The results were normalized to the starting amount of total RNA and are in good agreement with findings from the pooled libraries (Fig. 6B,C).

**Discussion**

GCPII is a potential pharmaceutical target for a number of pathological conditions caused by glutamate excitotoxicity in the central nervous system, including stroke and traumatic brain injury. Moreover, GCPII has been intensively studied as a target for diagnosis and treatment of prostate cancer, as it is overexpressed in the malignant prostate. In last two decades, a large
Fig. 3. Western blot analysis of GCPII expression in a panel of mouse tissues. Mouse tissue samples (from three males and three females) were homogenized, and lysates were resolved by SDS/PAGE (50 µg of total protein per lane). Mouse GCPII was visualized using the anti-GCPII primary antibody GCP-04 [2] and HRP-conjugated goat anti-mouse secondary antibody.

Fig. 4. GCPII expression in mouse tissues determined by radioenzymatic assay. The amount of GCPII in mouse tissues was determined by radioenzymatic assay using [3H]NAAG as a substrate and recombinant mouse GCPII (Avi-mGCPII) as a standard. Each tissue sample was measured in duplicate using 1–50 µg total protein in the reaction; the amount of mouse GCPII was normalized to total protein concentration (ng GCPII per mg total protein). The assay was performed with the same tissue samples used in the western blot analysis. *Not determined (adrenal gland: sample M1; eye: sample F1).
number of papers have been published describing novel GCPII inhibitors acting as neuroprotective drugs [28,44] and GCPII inhibitor-based tools for imaging and/or treating prostate cancer [19,20,45–47]. Most of these compounds and methods were evaluated using mouse models. However, there has been no direct comparison of mouse and human GCPII, which would provide important information to assess the usefulness of such mouse models. Therefore, we set out to perform a systematic and detailed study to compare the enzymatic properties of mouse and human GCPII, as well as tissue distributions on both the mRNA and protein levels.

We expressed the recombinant extracellular part of mouse GCPII with an N-terminal Avi-tag (Avi-mGCPII), which enables fast and efficient one-step purification [34]. Even though GCPII is a transmembrane enzyme, its extracellular domain is the catalytically active portion and correctly represents endogenous full-length GCPII [33]. To compare the enzymatic properties of mouse and human GCPII, we analyzed the cleavage of their substrates: N-acetyl-L-aspartyl-L-glutamate (NAAG), which is cleaved by GCPII in the brain, and pteroyl-di-L-glutamate, which is a model substrate for poly-gamma-glutamylated folates hydrolyzed by GCPII in the small intestine. Because mouse and human GCPII have high sequence similarity (86% identity and 97% similarity in the extracellular part; Fig. 7), we did not expect to find any significant differences in their enzymatic

Fig. 5. Immunohistochemical staining of chosen mouse tissue sections. Formalin-fixed, paraffin-embedded mouse tissue sections were incubated with anti-GCPII antibody GCP-04 (at 10 μg·mL⁻¹ concentration) to visualize and localize mouse GCPII expression [42]. (A) Brain (cerebellum): positive choroid plexus, stratum granulare, white matter. (B) Kidney: positive luminal side of proximal tubules, Bowman capsule; little crossreactivity of secondary anti-mouse antibody with capillaries and blood vessels could be seen in the negative control. (C) Sublingual gland: positive staining of abluminal cells (probably myoepitelial cells). (D) Submandibular gland: faint staining of intercalated ducts and some non-glandular abluminal cells. (E) Parotid gland: faint staining of some non-glandular abluminal cells.
properties. In fact, we found that while the enzymes are quite similar in NAAG-hydrolyzing activity, there is an order-of-magnitude difference in their catalytic efficiencies for cleavage of pteroyl-di-L-glutamate. This difference lies in the $K_M$ values of mouse and human GCPII (290 vs. 39 nM for pteroyl-di-L-glutamate and
**Fig. 7.** Sequence alignment of the mouse and human GCPII proteins. Identical amino acid residues are highlighted in yellow, similar residues in green, and different residues in white. A blue frame marks the internalization signal MXXXL [54], and a black frame corresponds to predicted GCPII transmembrane domain (predicted by TMHMM Server v. 2.0). Black circles denote potential N-glycosylation sites (‘N-X-S/T’). Green spheres: residues defining the S1’ pocket [49]; red spheres: residues forming the S1 pocket [48]; purple sphere: proton shuttle catalytic base [55]; blue spheres: zinc ligands [56,57].
1900 vs. 550 nm for NAAG). Their turnover numbers are quite similar (3.6 vs. 5.1 s\(^{-1}\) and 1.4 vs. 1.5 s\(^{-1}\), respectively) (see Table 1). Slightly surprisingly, our data revealed that the catalytic efficiency of NAAG cleavage by mouse and human GCPII is significantly lower than that of pteroyl-di-L-glutamate cleavage (20-fold and 50-fold, respectively) (see Table 1).

Additionally, we analyzed the inhibition profile of Avi-mGCPII using several GCPII inhibitors commonly used in research, including 2-PMPA, ZJ-43, DCIBzL, DKFZ-PSMA-11, and quisqualate. We also tested several other inhibitors that were prepared in our laboratory. Generally, we did not observe considerable differences in the \(K_i\) values obtained for mouse and human GCPII. However, inhibitors ZJ-43 and JB-277 were exceptions; the \(K_i\) values for Avi-mGCPII were 10-fold higher (Table 2). Both compounds belong to the urea-based group of GCPII inhibitors, together with DCIBzL. Surprisingly, the \(K_i\) value of DCIBzL was identical for both enzymes. As seen in Fig. 7, mouse and human GCPII are highly similar and key amino acid residues participating in substrate binding and hydrolysis are identical [48–50]. Thus, in the absence of an experimentally determined structure of mouse GCPII, it is difficult to explain the observed differences in inhibitor binding and catalytic efficiency.

Next, we assessed the substrate specificity of Avi-mGCPII. We screened dipeptide libraries covering almost all N-acetylated dipeptide substrates, not including cysteine-containing dipeptides. Unsurprisingly, mouse GCPII exhibited a strong preference for glutamate in the P1\(^{\prime}\) position, cleaving almost any dipeptide with a C-terminal glutamate (i.e., glutamate carboxypeptidase activity). It also cleaves dipeptides with methionine in the P1\(^{\prime}\) position and an acidic amino acid (aspartate or glutamate) in the P1 position. Dipeptides containing any other C-terminal amino acid were not hydrolyzed by mouse GCPII. The substrate specificity of mouse GCPII thus seems to be even more pronounced than that of the human enzyme (Fig. 2).

In addition to the enzymatic properties of mouse GCPII, its tissue distribution is a relevant aspect both to understand the physiological function of the enzyme and to assess the use of mouse models for targeted drug delivery and GCPII inhibition experiments. Therefore, we set out to elucidate GCPII expression in mouse tissues. To see individual differences, we collected tissue samples from six mice (three females and three males).

To assess GCPII expression on the protein level, we prepared mouse tissue lysates and detected mouse GCPII by western blot using the anti-GCPII antibody GCP-04, which was raised against human GCPII [2,42]. Because GCP-04 recognizes a linear epitope in the GCPII primary structure (amino acids 100–104: WKEFG [22]), which is conserved in the mouse GCPII sequence, the antibody can be used for selective and sensitive detection of mouse GCPII as well. We confirmed very high expression of GCPII in the mouse kidney and high expression in the mouse brain, which is in agreement with high GCPII expression in the corresponding human tissues [22]. Furthermore, we observed high expression of GCPII in the mouse major salivary glands. Relatively high variability among individual samples of major salivary glands is probably caused by close association of salivary glands that are macroscopically quite similar. This makes the proper dissection of topographically complicated ventral cervical region particularly cumbersome and might lead to cross-contamination. Therefore, we localized GCPII expression by immunohistochemistry using anti-GCPII antibody GCP-04. We observed GCPII expression in all three salivary glands (sublingual, submandibular, and parotid); however, GCPII is expressed predominantly in the sublingual gland, while the expression in the submandibular and parotid glands is lower (Fig. 5).

Mouse prostate contains negligible levels of GCPII, which is consistent with previous findings [9] and in contrast with human prostate, which expresses large amounts of GCPII [6,22,51]. Additionally, as human and mouse prostates differ considerably in their morphology, we dissected a mouse prostate into its individual parts (anterior, dorsal, and lateral prostate) and searched for potential GCPII expression in each part separately. Nevertheless, we did not detect GCPII expression in any of the tested parts of mouse prostate. Our data suggest that GCPII might also be absent in the mouse jejunum, a tissue where human GCPII cleaves off glutamates from glutamylated folates [17]. Rat jejunum and ileum were shown not to contain GCPII, in contrast to the corresponding human tissues, which express large amounts of GCPII [22]. Folates in rat intestine are hydrolyzed by \(\gamma\)-glutamyl hydrolase, not GCPII [52], and the situation in mice may be thus similar.

Furthermore, we verified GCPII tissue distribution obtained by western blot analysis by quantification of NAAG-hydrolyzing activity in mouse tissues. The activity-based GCPII expression profile correlated well with the western blot results, confirming strong GCPII expression in the mouse kidney, brain, and salivary glands and no expression in mouse prostate and jejunum.

GCPIII is a close GCPII homolog found both in humans and in mouse. The GCP-04 antibody also
recognizes GCPIII but is roughly 10-fold less sensitive toward GCPIII than toward GCPII [42]. Moreover, GCPIII also hydrolyzes NAAG, although with a lower catalytic efficiency [10,11,43]. Therefore, GCPII distribution in mouse tissues obtained by western blot analysis with GCP-04 and activity assay based on NAAG hydrolysis could be distorted by a high amount of GCPIII and low amount of GCPII in a particular tissue. Because there is no specific antibody against GCPIII, we explored GCPII/GCPIII expression in mouse tissues on the mRNA level to differentiate between the two homologs. We quantified GCPII and GCPIII transcripts in both commercially available mouse tissue cDNA libraries and cDNA libraries we prepared from isolated mouse tissues (Fig. 6). Taking these qPCR data into account, GCPIII appears to be the source of the NAAG-hydrolyzing activity in the mouse ovary, uterus, and heart. GCPIII was most strongly expressed in the testis but was accompanied by rather high quantities of GCPII.

To conclude, we prepared and characterized recombinant mouse GCPII and compared it with human GCPII. We found that the differences in enzymatic activity, inhibition profile, and substrate specificity between mouse and human GCPII are rather small; therefore, mouse GCPII can serve as a suitable substitute for human GCPII in enzymological studies.

Due to the observed lack of GCPII expression in the mouse prostate, mouse might not seem to be an ideal model for the development of prostate cancer diagnostic/therapeutic agents. However, most such studies employ human tumor xenografts in mouse models. For this purpose, mice are generally suitable, because the distribution of GCPII in other tissues is quite similar to that in humans. Therefore, mouse GCPII appears to be a good model for the development of GCPII-targeted drugs for treatment of prostate cancer and neuronal disorders.

**Experimental procedures**

**Cloning of mouse GCPII (Avi-mGCPII)**

The pIRES/mGCPII plasmid encoding full-length mouse GCPII (amino acids 1-752) was a kind gift from Warren Heston (Cleveland Clinic, USA).

Because the sequence contained two conflicts compared to the annotated mouse GCPII sequence, we performed site-directed mutagenesis to remove them (G240A and E287N). The primers 5'-gtacctggtgactcctc-c-tctcc-3' and 5'-gctggagctcctcGCGagactgctc-3' were used to remove the sequence conflict at position 240, and the primers 5'-catggtgacAAACggtgacctcc-3' and 5'-gaaagccagacGCTgtaactcagac-3' to remove the sequence conflict at position 287 (changed deoxyribonucleotides are underlined, changed codons capitalized). The mutagenesis was carried out according to the manufacturer’s protocol (QuikChange™ Site-Directed Mutagenesis; Stratagene, San Diego, CA, USA).

Then, the sequence corresponding to the extracellular part of mouse GCPII (amino acids 45-752) was amplified by PCR using primers 5'-aaatgataactctcaagatgactggac-3' and 5'-aaactgcagtagactcctccagtc-3' (restriction sites introduced into the sequence are underlined; the primers introduced a BglII site at the 5' end and an XhoI site at the 3' end). The resulting DNA fragment was cleaved with BglII and XhoI and ligated into pMT/BiP/rhGCPII plasmid [34] cleaved with the same endonucleases. The correct sequence of the resulting plasmid pMT/BiP/Avi-mGCPII was verified by DNA sequencing.

**Transfection of Drosophila S2 cells and expression of Avi-mGCPII**

*Drosophila* S2 cells expressing BirA biotin-protein ligase localized in the endoplasmic reticulum (described in Ref. [34]) were used to prepare stable Avi-mGCPII transfectants. The cells were transfected using Calcium Phosphate Transfection Kit (Invitrogen, Waltham, MA, USA) with 9 μg of pMT/BiP/Avi-mGCPII together with 0.5 μg of pCoBlast (Invitrogen), as previously described [10]. The transfected cells were cultivated in the presence of both blasticidin (5 μg·mL⁻¹, Invitrogen) and hygromycin B (300 μg·mL⁻¹; Invitrogen).

To express Avi-mGCPII, approximately 2 × 10⁶ stably transfected cells was transferred into a 35-mm Petri dish supplemented with 2 mL SF900II medium (Invitrogen). The following day, protein expression was induced by adding CuSO₄ (Sigma-Aldrich, St. Louis, MO, USA) to a final concentration of 1 mM. After three days, cells were harvested by centrifugation, and the medium was analyzed by western blot.

The large-scale expression of Avi-mGCPII was performed as previously described [33]. The final volume of cell suspension was 1000 mL.

**Purification of Avi-mGCPII**

Purification of Avi-mGCPII was performed as previously described [34]. Briefly, cell medium (1000 mL) containing secreted biotinylated Avi-mGCPII was centrifuged at 3400 g for 45 min. Then, it was concentrated 10-fold using a LabScale TFF System (Merck Millipore, Billerica, MA, USA) with a Pellicon™ XL 50 Cassette, Biomax 100. The concentrated medium was centrifuged again at 3400 g for 20 min and equilibrated with 300 mM Tris/HCl, 450 mM NaCl, pH 7.2 in a 2:1 ratio. The equilibrated...
concentrated Avi-mGCPII medium was then mixed with 1 mL Streptavidin Mutein Matrix (Roche, Basel, Switzerland) and incubated with gentle shaking at 6 °C for 15 h. Afterward, the resin was washed with 50 column volumes of 100 mM Tris/HCl, 150 mM NaCl, pH 7.2. Bound biotinylated proteins were eluted with 5 mL of 100 mM Tris/HCl, 150 mM NaCl, 2 mM D-biotin, pH 7.2, in five consecutive elution fractions (after the first elution fraction, the resin was incubated with elution buffer for 1 h). After regeneration of the resin, the flow-through fraction was again mixed with the resin, and the purification procedure was repeated.

**Determination of kinetic parameters by radioenzymatic assay**

Kinetic parameters ($K_M$ and $k_{cat}$) of N-acetyl-l-aspartyl-l-glutamate (NAAG) cleavage by Avi-mGCPII were determined as previously described [34], with a minor modification: The reactions were performed in a 96-well plate, and appropriate amounts of Avi-mGCPII were mixed with 25 mM Bis-Tris propane, 150 mM NaCl, 0.001% octaethylene glycol monododecyl ether (Affymetrix, Santa Clara, CA, USA), pH 7.4.

**Determination of kinetic and inhibition constants by HPLC**

Kinetic parameters ($K_M$ and $k_{cat}$) of pteroyl-di-l-glutamate cleavage by Avi-mGCPII, as well as $K_i$ values for all inhibitors, were determined as previously described [39]. Briefly, in a 96-well plate, Avi-mGCPII was mixed with 25 mM Bis-Tris propane, 150 mM NaCl, 0.001% octaethylene glycol monododecyl ether (Affymetrix), pH 7.4 (and tested inhibitor, if used), into a final volume of 90 μL. Reactions were started by adding 10 μL of 1 μM NAAG (containing 50 nM tritium-labeled NAAG), and incubated at 37 °C for 15 h. The reactions were stopped with 100 μL of ice-cold 200 mM KH2PO4, 2 mM 2-mercaptoethanol, pH 7.4. The released glutamate was separated from the unreacted substrate using ion-exchange AG1-X resin (Bio-Rad). The radioactivity of the sample was quantified by liquid scintillation using the Rotiszint ECO Plus scintillation cocktail (Roth) in a Tri-Carb Liquid Scintillation Counter (Perkin-Elmer, Waltham, MA, USA). The samples were measured in duplicate.

**Tissue lysate sample preparation**

A small piece of tissue (approx. 30 mg) was transferred into 250 μL of 50 mM Tris/HCl, 100 mM NaCl, pH 7.4, in a 2-mL microtube. Tissue samples were homogenized using TissueLyser II (30 Hz, 3 min). The homogenates were then diluted with 250 μL of the lysis buffer. Octaethylene glycol monododecyl ether (Affymetrix) was added to reach 1% final concentration, and the homogenate was sonicated in a water bath for 5 min at 0 °C. Finally, the samples were centrifuged at 600 g for 15 min, and the resulting supernatant was stored at −80 °C until further use. The lysate protein concentration was determined using Bradford 1 × Dye Reagent (Bio-Rad, Hercules, CA, USA).

**Radioenzymatic determination of NAAG-hydrolyzing activity in mouse tissues**

The determination of NAAG-hydrolyzing activity in mouse tissues was performed as previously described [53]. A sample of tissue lysate was mixed with 20 mM Tris/HCl, 150 mM NaCl, 0.1% Tween 20, pH 7.4, to a final volume of 90 μL. Reactions were started by adding 10 μL of 1 μM NAAG (containing 50 mM tritium-labeled NAAG), and incubated at 37 °C for 15 h. The reactions were stopped with 100 μL of ice-cold 200 mM KH2PO4, 2 mM 2-mercaptoethanol, pH 7.4. The released glutamate was then separated from the unreacted substrate using ion-exchange AG1-X resin (Bio-Rad). The radioactivity of the sample was quantified by liquid scintillation using the Rotiszint ECO Plus scintillation cocktail (Roth) in a Tri-Carb Liquid Scintillation Counter (Perkin-Elmer, Waltham, MA, USA). The samples were measured in duplicate.

**SDS/PAGE and western blotting**

Protein samples were resolved by reducing SDS/PAGE. Proteins were electroblotted onto a nitrocellulose membrane (wet blotting: 100 V/1 h). After blotting, the membrane was blocked with 0.55% (w/v) casein solution in PBS (Casein Buffer 20X-4X Concentrate, SDT, Baesweiler, Germany) at room temperature for 1 h. To visualize GCPII, the blots were probed with the antibody GCP-04 (described in [2]) for 12 h at 4 °C (200 ng·mL−1; diluted in 0.55% casein solution), washed three times with PBS containing 0.05% Tween 20 (PBST buffer), and incubated with goat anti-mouse antibody conjugated with horseradish peroxidase (Thermo Scientific, Waltham, MA, USA; diluted in 0.55% casein solution, 1:25 000). The blots were then washed three times with PBST to remove unbound antibodies and developed with SuperSignal West Femto Chemiluminescent Substrate (Thermo Scientific).
Chemiluminescence was captured with a ChemiDoc-It™ 600 Imaging System (UVP, Upland, CA, USA).

**Immunohistochemistry**

Immunohistochemistry was performed according to the protocol described previously using anti-GCPII antibody GCP-04 [2] with minor modifications [42]. Briefly, after standard histological processing (fixation, dehydration, embedding into paraffin, cutting, paraffin removal, rehydration), heat antigen retrieval was performed using 10 mM sodium citrate, 0.1% Tween 20, pH 6.0 buffer and heating to 110 °C for 15 min in an autoclave. Afterward, samples were incubated in 1.5% hydrogen peroxide solution for 20 min to reduce endogenous peroxidase activity and in 10% fetal bovine serum in PBS to block unspecific interactions. The slides were then stained by primary anti-GCPII antibody GCP-04 (10 μg·mL⁻¹ in 4 °C, overnight), followed by extensive washing (five times with PBS containing 0.1% Tween 20) and incubation with secondary antibody Histofine™ Simple Stain™ MAX PO (MULTI) (Nichirei Bioscience Inc., Tokyo, Japan) diluted 1 : 2 with 10% fetal bovine serum in PBS at room temperature for 1 h. After further extensive washing (five times with PBS containing 0.1% Tween 20), GCPII was visualized using DAB/Plus kit (Diagnostic BioSystems, Pleasanton, CA, USA, 60 s). The slides were counterstained with Harris’ hematoxylin and mounted in polyvinyl alcohol-based media.

**Carboxypeptidase activity assay**

Carboxypeptidase activity (i.e., substrate specificity) of mouse GCPII was determined using N-Ac-A-X peptide libraries according to a previously published method [41]. Briefly, 1.2 μg Avi-mGCPII was diluted into 25 mM Bis-Tris propane, 150 mM NaCl, 0.001% octaethylene glycol monododecylether (Aftymatrix), pH 7.4, and incubated in the presence of 25 μM dipeptide for 1.5 h at 37 °C. As negative controls, reactions without the enzyme and in the presence of 1 mM 2-PMPA, a highly selective GCPII inhibitor, were performed. The reaction mixture was then analyzed using HPLC, as previously described [41].

**Total RNA isolation and reverse transcription**

First, tissue samples were transferred from RNA later solution (Invitrogen, #AM7021) to RLT buffer (part of the RNeasy Mini Kit, Qiagen, Hilden, Germany, #74106) supplied with β-mercaptoethanol and homogenized with 5-mm steel beads (Qiagen; #69989) using TissueLyser II (#85300; Qiagen). Total RNA was isolated using RNeasy Mini Kit according to the manufacturer’s instructions. The concentration and purity of isolated RNA were determined spectrophotometrically using a Nanodrop ND-1000 spectrophotometer. The integrity of each RNA sample was analyzed using the Agilent RNA 6000 Nano kit run on an Agilent 2100 Bioanalyzer. Only samples without significant degradation were used for subsequent steps.

RNA was then reverse-transcribed using M-MLV (≥28025013; Invitrogen) according to the manufacturer’s instructions. Each 20 μL reaction contained up to 2 μg total RNA, 2.5 μM oligo(dT)₂₀ primers (≥18418020; Invitrogen), 50 ng random hexamers (100 ng if more than 1 μg RNA was transcribed), 40 units of RNaseOUT, 200 units of M-MLV reverse transcriptase, and other components as specified by the manufacturer.

**Quantitative PCR (qPCR) analysis**

All qPCRs were carried out in triplicate in FrameStar 480/96 multiwell plates (≥4ti-0951; 4titude, Wotton, UK) sealed with adhesive optical foil (≥4729692001; Roche) using a LightCycler 480 II instrument (Roche) in a total volume of 10 μL. Each reaction consisted of LightCycler 480 Probe Master (Roche) diluted according to the manufacturer’s instructions, forward and reverse primers (1 μM final concentration each), fluorescent probe (see description of individual assays for final concentration), and 1 μL of sample or template DNA (positive and nontemplate controls as well as interplate calibrators were included on each plate). Initial denaturation for 3 min at 95 °C was followed by 45 cycles of 10 s at 95 °C, 30 s at 66 °C, and 30 s at 72 °C. The threshold cycle numbers (C₅₀) were then determined from fluorescence intensities acquired during the qPCR runs by the second-derivative maximum method using LightCycler 480 software (Roche). The presence and size of PCR products were analyzed by agarose gel electrophoresis.

The amount of mouse GCPII (encoded by the gene Folh1) was quantified by an assay set of forward and reverse primers (sequences 5'-gatgtccgcatatggaatggtgagc-3' and 5'-gctgtcaggcttatttatttt-3') and fluorescent hydrolysis probe #6 from the Roche Universal Probe Library (LNA octamer sequence 5'-cagagggaa-3'; final concentration 100 nm). This set was designed to amplify nucleotides 714–773 in mouse GCPII transcript NM_016770 to yield an amplified product of 60 bps, which spans the region of exons 5 and 6 and corresponds to amino acids 202–223 in the longest open reading frame (ORF). This assay should not amplify genomic sequence because it spans a 1029-bp intron.

The amount of mouse GCPIII transcript (encoded by the gene Naalad2) was quantified by an assay set of forward and reverse primers (sequences 5'-aatgatgcagagagac-3' and 5'-aatgatgcagagagac-3') and fluorescent hydrolysis probe #52 from the Roche Universal Probe Library (LNA octamer sequence 5'-aggaggag-3'; final concentration 50 nm). This set was designed to amplify nucleotides 922–981 in mouse GCPIII transcript NM_028279 to yield an amplified product of 60 bps, which spans the region of exons 7 and 8 and corresponds to
amino acids 289–309 in the longest ORF. This assay should not amplify genomic sequence because it spans a 880-bp intron.

As a standard for absolute quantification, serial 10-fold dilutions covering concentrations from $10^0$ to $10^3$ copies per reaction of either pcDNA4 plasmid with subcloned coding sequence of full-length mouse GCPII (longest ORF from NM_016770 coding amino acids 1–752) or pMT/BiP plasmid with subcloned coding sequence of extracellular part of mouse GCPIII (part of longest ORF from NM_028279 coding amino acids 36–740) were amplified with the corresponding assay set. The initial concentration of plasmid DNA (purified by QIAprep Spin Miniprep Kit, #27106; Qiagen) prior to dilution was determined spectrophotometrically at 260 nm (Nanodrop ND-1000; Thermo Scientific).

To enable precise absolute comparison between the determined amounts of both transcripts, obtained calibration curves were further normalized against each other by quantification of a common region of both plasmids. The region containing the ampicillin resistance gene was quantified by a set of primers with sequences 5'-gcagaattccagcaacaatta-3' and 5'-agcttcccggcaacaatta-3' and fluorescent hydrolysis probe #58 from the Roche Universal Probe Library (final concentration 50 nM). In this way, two calibration curves were obtained for each plasmid, one for the amplification of target transcript and one for the common sequence. Finally, the slope and intercept values of both curves were transformed for each plasmid so that the transformed slope and intercept values of the curves for the common sequence were equal between the two plasmids and corresponded to the average value between the two plasmids.

The amount of both transcripts was determined in the prepared tissue cDNA libraries. In each qPCR, an amount of cDNA corresponding to the starting amount of total RNA of 5–10 ng was used, and the amount of GCPII and GCPIII transcripts were normalized to the total amount of RNA. Both transcripts were also quantified in 1.0 μL of 10-fold diluted commercial tissue cDNA libraries (Mouse MTC Panels I and III supplied by Clontech, Mountain View, CA, USA, #636745 and 636757), which had been normalized to several control genes by the vendor (beta-actin, G3PDH, phospholipase A2, and ribosomal protein S29).

Statistical analysis

All values are presented as the mean ± standard deviation.

Acknowledgements

We would like to thank Warren Heston (Lerner Research Institute, Cleveland Clinic) for providing us with a plasmid encoding mouse GCPII, Jana Starková and Karolína Šrámková for their excellent technical support, Radko Souček for HPLC analyses, and Hilary Hoffman for language editing. This work was supported by Grant No. GA16-02938S from the Grant Agency of the Czech Republic and InterBioMed Project LO 1302 from the Ministry of Education of the Czech Republic.

Author contributions

The manuscript was written through contributions of all authors. All authors have given approval to the final version of the manuscript. JK and PS conceived the project and analyzed data, TK, BV, JT, VN, PS and JK wrote the manuscript, TK, BV, VN, JT, FS, SV and MF designed, performed and interpreted the experiments.

References

1 Berger UV, Carter RE, Mckee M and Coyle JT (1995) N-acetylated alpha-linked acidic dipeptidase is expressed by non-myelinating Schwann-cells in the peripheral nervous-system. J Neurocytol 24, 99–109.
2 Sacha P, Zamecnik J, Barinka C, Hlouchova K, Vicha A, Mlechová P, Hilgert I, Eckschlager T and Konvalinka J (2007) Expression of glutamate carboxypeptidase II in human brain. Neuroscience 144, 1361–1372.
3 Bostwick DG, Pacelli A, Blute M, Roche P and Murphy GP (1998) Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 82, 2256–2261.
4 Silver DA, Pellicer I, Fair WR, Heston WD and Cordon-Cardo C (1997) Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 3, 81–85.
5 Pinto JT, Scaffoletto BP, Berzin TM, Qiao CH, Lin SL, Tong WP, May F, Mukherjee B and Heston WDW (1996) Prostate-specific membrane antigen: a novel folate hydrolase in human prostatic carcinoma cells. Clin Cancer Res 2, 1445–1451.
6 Kinoshita Y, Kuratsukuri K, Landas S, Imaida K, Rovito PM Jr, Wang CY and Haas GP (2006) Expression of prostate-specific membrane antigen in normal and malignant human tissues. World J Surg 30, 628–636.
7 Robinson MB, Blakely RD, Couto R and Coyle JT (1987) Hydrolysis of the brain dipeptide N-acetyl-L-aspartyl-L-glutamate. Identification and characterization of a novel N-acetylated alpha-linked acidic dipeptidase activity from rat brain. J Biol Chem 262, 14498–14506.
Characterization of mouse GCPII

8 Horoszewicz JS, Kawinski E and Murphy GP (1987) Monoclonal-antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic-cancer patients. *Anticancer Res* 7, 927–936.

9 Bacich DJ, Ramadan E, O'Keefe DS, Bukhari N, Wegorzewskia I, Ojeifo O, Olszewski R, Wrenn CC, Bzdega T, Wroblewska B et al. (2002) Deletion of the glutamate carboxypeptidase II gene in mice reveals a second enzyme activity that hydrolyzes N-acetylaspartylglutamate. *J Neurochem* 83, 20–29.

10 Hlouchova K, Barinka C, Klusak V, Sacha P, Mlochova P, Majer P, Rulisek L and Konvalinka J (2007) Biochemical characterization of human glutamate carboxypeptidase III. *J Neurochem* 101, 682–696.

11 Collard F, Vertommen D, Constantinescu S, Buts L and Van Schaftingen E (2011) Molecular identification of beta-citrylglutamate hydrolase as glutamate carboxypeptidase 3. *J Biol Chem* 286, 38220–38230.

12 Slusher BS, Vornov JJ, Thomas AG, Hurn PD, Harukuni I, Bhardwaj A, Traystman RJ, Robinson MB, Britton P, Lu XCM et al. (1999) Selective inhibition of NAALADase, which converts NAAG to glutamate, reduces ischemic brain injury. *Nat Med* 5, 1396–1402.

13 Neale JH, Olszewski RT, Gehl LM, Wroblewska B and Bzdega T (2005) The neurotransmitter N-acetylaspartylglutamate in models of pain, ALS, diabetic neuropathy, CNS injury and schizophrenia. *Trends Pharmacol Sci* 26, 477–484.

14 Wroblewska B, Wroblewska JT, Pshenichkin S, Surin A, Sullivan SE and Neale JH (1997) N-acetylaspartylglutamate selectively activates mGlur3 receptors in transfected cells. *J Neurochem* 69, 174–181.

15 Bruno V, Wroblewska B, Wroblewska JT, Fiore L and Nicoletti F (1998) Neuroprotective activity of N-acetylaspartylglutamate in cultured cortical cells. *Neuroscience* 85, 751–757.

16 Halsted CH, Ling EH, Luthi-Carter R, Villanueva JA, Gardner JM and Coyle JT (1998) Folylypoly-gamma-glutamate carboxypeptidase from pig jejenum – molecular characterization and relation to glutamate carboxypeptidase II. *J Biol Chem* 273, 20417–20424.

17 Chandler CJ, Wang TT and Halsted CH (1986) Pteroylpolyglutamate hydrolase from human jejunal brush borders. Purification and characterization. *J Biol Chem* 261, 928–933.

18 Mhawech-Fauceglia P, Zhang S, Terracciano L, Sauter G, Chadhuri A, Herrmann FR and Penetrante R (2007) Prostate-specific membrane antigen (PSMA) protein expression in normal and neoplastic tissues and its sensitivity and specificity in prostate adenocarcinoma: an immunohistochemical study using multiple tumour tissue microarray technique. *Histopathology* 50, 472–483.

19 Chen Z, Penet MF, Nimmagadda S, Li C, Banerjee SR, Winnard PT Jr, Artemov D, Glunde K, Pomper MG and Bhujwalla ZM (2012) PSMA-targeted theranostic nanoplex for prostate cancer therapy. *ACS Nano* 6, 7752–7762.

20 Heck MM, Retz M, D’Alessandria C, Rauscher I, Scheidhauer K, Maurer T, Storz E, Janssen F, Schottelius M, Wester HJ et al. (2016) Systemic radioligand therapy with (177)Lu labeled specific membrane antigen ligand for imaging and therapy in patients with metastatic castration resistant prostate cancer. *J Urol* 196, 382–391.

21 Hrkach J, Von Hoff D, Ali MM, Andrianova E, Auer J, Campbell T, De Witt D, Figa M, Figueiredo M, Horhota A et al. (2012) Preclinical development and clinical translation of a PSMA-targeted docetaxel nanoparticle with a differentiated pharmacological profile. *Sci Transl Med* 4, 128ra39.

22 Rovenska M, Hlouchova K, Sacha P, Mlochova P, Horak V, Zamecnik J, Barinka C and Konvalinka J (2008) Tissue expression and enzymologic characterization of human prostate specific membrane antigen and its rat and pig orthologs. *Prostate* 68, 171–182.

23 Zhong C, Zhao X, Van KC, Bzdega T, Smyth A, Zhou J, Kozikowski AP, Jiang J, O’Connor WT, Berman RF et al. (2006) NAAG peptidase inhibitor increases dialysate NAAG and reduces glutamate, aspartate and GABA levels in the dorsal hippocampus following fluid percussion injury in the rat. *J Neurochem* 97, 1015–1025.

24 Zhong CL, Zhao XR, Sarva J, Kozikowski A, Neale JH and Lyeth BG (2005) NAAG peptidase inhibitor reduces acute neuronal degeneration and astrocyte damage following lateral fluid percussion TBI in rats. *J Neurotrauma* 22, 266–276.

25 Ghadge GD, Slusher BS, Bodner A, Canto MD, Wozniak K, Thomas AG, Rojas C, Tsukamoto T, Majer P, Miller RJ et al. (2003) Glutamate carboxypeptidase II inhibition protects motor neurons from death in familial amyotrophic lateral sclerosis models. *Proc Natl Acad Sci USA* 100, 9554–9559.

26 Chen SR, Wozniak KM, Slusher BS and Pan HL (2002) Effect of 2-(phosphono-methyl)-pentanedioic acid on allodynia and afferent ectopic discharges in a rat model of neuropathic pain. *J Pharmacol Exp Ther* 300, 662–667.

27 Nagel J, Belozertsve I, Greco S, Kashkin V, Malyshekin A, Jirgensons A, Shekunova E, Eibacher B, Bespalov A and Damysz W (2006) Effects of NAAG peptidase inhibitor 2-PMPA in model chronic pain – relation to brain concentration. *Neuropharmacology* 51, 1163–1171.

28 Zhou J, Neale JH, Pomper MG and Kozikowski AP (2005) NAAG peptidase inhibitors and their potential
Characterization of mouse GCPII

T. Knedlik et al.

for diagnosis and therapy. Nat Rev Drug Discov 4, 1015–1026.

29 Bacich DJ, Pinto JT, Tong WP and Heston WD (2001) Cloning, expression, genomic localization, and enzymatic activities of the mouse homolog of prostate-specific membrane antigen/NAALADase/folate hydrolase. Mamm Genome 12, 117–123.

30 Gao Y, Xu SY, Cui ZW, Zhang MK, Lin YY, Cai L, Wang ZG, Luo XG, Zheng Y, Wang Y et al. (2015) Mice lacking glutamate carboxypeptidase II develop normally, but are less susceptible to traumatic brain injury. J Neurochem 134, 340–353.

31 Tsai G, Dunham KS, Drager U, Grier A, Anderson C, Collura J and Coyle JT (2003) Early embryonic death of glutamate carboxypeptidase II (NAALADase) homozygous mutants. Synapse 50, 285–292.

32 Han LQ, Picker JD, Schaevitz LR, Tsai GC, Feng JM, Jiang ZC, Chu HC, Basu AC, Berger-Sweeney J and Coyle JT (2009) Phenotypic characterization of mice heterozygous for a null mutation of glutamate carboxypeptidase II. Synapse 63, 625–635.

33 Barinka C, Rinnova M, Sacha P, Rojas C, Majer P, Slusher BS and Konvalinka J (2002) Substrate specificity, inhibition and enzymological analysis of recombinant human glutamate carboxypeptidase II. J Neurochem 80, 477–487.

34 Tykvart J, Sacha P, Barinka C, Knedlik T, Starkova J, Lubkowski J and Konvalinka J (2012) Efficient and versatile one-step affinity purification of in vivo biotinylated proteins: expression, characterization and structure analysis of recombinant human glutamate carboxypeptidase II. Protein Expr Purif 82, 106–115.

35 Jackson PF, Cole DC, Slusher BS, Stetz SL, Ross LE, Donzanti BA and Trainor DA (1996) Design, synthesis, and biological activity of a potent inhibitor of the neuropeptidase N-acetylated alpha-linked acidic dipeptidase. J Med Chem 39, 619–622.

36 Kozikowski AP, Zhang J, Nan FJ, Petukhov PA, Grajkowska E, Wroblewska JT, Yamamoto T, Bzdega T, Wroblewska B and Neale JH (2004) Synthesis of urea-based inhibitors as active site probes of glutamate carboxypeptidase II: efficacy as analgesic agents. J Med Chem 47, 1729–1738.

37 Chen Y, Foss CA, Byun Y, Nimmagadda S, Pullambhatla M, Fox JJ, Castanares M, Lupold SE, Babich JW, Mease RC et al. (2008) Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer. J Med Chem 51, 7933–7943.

38 Eder M, Schäfer M, Bauder-Wust U, Hull WE, Wangel G, Mier W, Haberkorn U and Eisenhut M (2012) Ga-68-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem 23, 688–697.

39 Tykvart J, Schimer J, Barinkova J, Pachl P, Postovsky- Slavetinska L, Majer P, Konvalinka J and Sacha P (2014) Rational design of urea-based glutamate carboxypeptidase II (GCPII) inhibitors as versatile tools for specific drug targeting and delivery. Bioorg Med Chem 22, 4099–4108.

40 Tykvart J, Schimer J, Jancarik J, Barinkova J, Navratil V, Starkova J, Sramkova K, Konvalinka J, Majer P and Sacha P (2015) Design of highly potent urea-based, exosite-binding inhibitors selective for glutamate carboxypeptidase II. J Med Chem 58, 4357–4363.

41 Tykvart J, Barinka C, Svoboda M, Navratil V, Sourcek R, Hubalek M, Hradilek M, Sacha P, Lubkowski J and Konvalinka J (2015) Structural and biochemical characterization of a novel aminopeptidase from human intestine. J Biol Chem 290, 11321–11336.

42 Tykvart J, Navratil V, Sledlak F, Corey E, Colombatti M, Fracasso G, Koukolik F, Barinka C, Sacha P and Konvalinka J (2014) Comparative analysis of monoclonal antibodies against prostate-specific membrane antigen antibody (PSMA). Prostate 74, 1674–1690.

43 Navratil M, Tykvart J, Schimer J, Pachl P, Navratil V, Rokob TA, Hlouchova K, Rulisek L and Konvalinka J (2016) Comparison of human glutamate carboxypeptidases II and III reveals their divergent substrate specificities. FEBS J 283, 2528–2545.

44 Majer P, Jancarik J, Krcemerova M, Tichy T, Tenora L, Wozniak K, Wu Y, Pommier E, Ferraris D, Rais R et al. (2016) Discovery of orally available prodrugs of the glutamate carboxypeptidase II (GCPII) inhibitor 2-phosphonomethylpentanedioic acid (2-PMPA). J Med Chem 59, 2810–2819.

45 Chen Y, Dhara S, Banerjee SR, Byun Y, Pullambhatla M, Mease RC and Pomper MG (2009) A low molecular weight PSMA-based fluorescent imaging agent for cancer. Biochem Biophys Res Commun 390, 624–629.

46 Gorin MA, Pomper MG and Rowe SP (2016) PSMA-targeted imaging of prostate cancer: the best is yet to come. BJU Int 117, 715–716.

47 Yang X, Mease RC, Pullambhatla M, Lisok A, Chen Y, Foss CA, Wang Y, Shallal H, Edelman H, Hoye AT et al. (2016) [(18)F]Fluorobenzoyllysinepentanedioic acid carbamates: new scaffolds for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA). J Med Chem 59, 206–218.

48 Barinka C, Hlouchova K, Rovenska M, Majer P, Dauter M, Hin N, Ko YS, Tsukamoto T, Slusher BS, Konvalinka J et al. (2008) Structural basis of interactions between human glutamate carboxypeptidase II and its substrate analogs. J Mol Biol 376, 1438–1450.

49 Barinka C, Rovenska M, Mlchova P, Hlouchova K, Plechanovova A, Majer P, Tsukamoto T, Slusher BS, Konvalinka J and Lubkowski J (2007) Structural
insight into the pharmacophore pocket of human glutamate carboxypeptidase II. J Med Chem 50, 3267–3273.

50 Mlcochova P, Plechanovova A, Barinka C, Mahadevan D, Saldanha JW, Rulisek L and Konvalinka J (2007) Mapping of the active site of glutamate carboxypeptidase II by site-directed mutagenesis. FEBS J 274, 4731–4741.

51 O’Keefe DS, Bacich DJ and Heston WD (2004) Comparative analysis of prostate-specific membrane antigen (PSMA) versus a prostate-specific membrane antigen-like gene. Prostate 58, 200–210.

52 Shafizadeh TB and Halsted CH (2007) Gamma-glutamyl hydrolase, not glutamate carboxypeptidase II, hydrolyzes dietary folate in rat small intestine. J Nutr 137, 1149–1153.

53 Knedlik T, Navratil V, Vik V, Pacik D, Sacha P and Konvalinka J (2014) Detection and quantitation of glutamate carboxypeptidase II in human blood. Prostate 74, 768–780.

54 Rajasekaran SA, Anilkumar G, Oshima E, Bowie JU, Liu H, Heston W, Bander NH and Rajasekaran AK (2003) A novel cytoplasmic tail MXXXL motif mediates the internalization of prostate-specific membrane antigen. Mol Biol Cell 14, 4835–4845.

55 Klusak V, Barinka C, Plechanovova A, Mlcochova P, Konvalinka J, Rulisek L and Lubkowski J (2009) Reaction mechanism of glutamate carboxypeptidase II revealed by mutagenesis, X-ray crystallography, and computational methods. Biochemistry 48, 4126–4138.

56 Mesters JR, Barinka C, Li WX, Tsukamoto T, Majer P, Slusher BS, Konvalinka J and Hilgenfeld R (2006) Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer. EMBO J 25, 1375–1384.

57 Speno HS, Luthi-Carter R, Macias WL, Valentine SL, Joshi ART and Coyle JT (1999) Site-directed mutagenesis of predicted active site residues in glutamate carboxypeptidase II. Mol Pharmacol 55, 179–185.